Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BIO Bio-Rad Laboratories
403.880
+4.290+1.07%
Post Mkt Price
403.8800.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-8.87% 680.8M -3.47% 691.1M -3.68% 700.06M 14.81% 2.92B
Operating revenue
-8.87% 680.8M -3.47% 691.1M -3.68% 700.06M 14.81% 2.92B
Cost of revenue
-0.84% 307.01M -6.11% 295.12M -9.10% 296.5M 15.71% 1.28B
Gross profit
-14.55% 373.79M -1.40% 395.98M 0.73% 403.56M 14.11% 1.64B
Operating expense
0.13% 281M -0.38% 275.76M -13.22% 260.14M 12.11% 1.15B
Selling and administrative expenses
-2.36% 211.05M -2.20% 208.73M -12.51% 197.59M 9.91% 879.57M
Research and development costs
8.48% 69.95M 5.75% 67.03M -15.38% 62.54M 19.88% 271.66M
Operating profit
-40.82% 92.8M -3.66% 120.22M 42.20% 143.42M 19.10% 489.43M
Net non-operating interest income expense
-404.55% -3.66M -1,648.96% -5.22M -917.09% -4.05M 573.89% 17.35M
Non-operating interest income
-- 8M 685.71% 5.5M -- -- 3.85% 18.9M
Non-operating interest expense
1,506.47% 11.66M 2,853.17% 10.72M 917.09% 4.05M -92.91% 1.55M
Other net income (expense)
-106.13% -298.26M -229.68% -1.34B -476.89% -4.51B 9.58% 4.93B
Gain on sale of security
-106.03% -293.56M -229.74% -1.34B -485.22% -4.54B 9.71% 4.93B
Special income (charges)
-- -5.1M -- 1.4M -- -- -111.27% -800K
-Less:Other special charges
-- 5.1M -- -- -- -- -- --
-Write off
-- 0 -- 0 -- -- -82.61% 800K
-Gain on sale of business
-- 0 -- 1.4M -- -- -- 0
Other non- operating income (expenses)
233.33% 400K 125.00% 200K 87.26% 32.6M 138.89% 700K
Income before tax
-104.16% -209.17M -205.71% -1.22B -436.96% -4.37B 10.81% 5.44B
Income tax
-104.11% -44.94M -221.86% -295.7M -413.15% -1B 8.25% 1.19B
Net income
-104.18% -164.23M -201.43% -927.18M -444.75% -3.37B 11.55% 4.25B
Net income continuous Operations
-104.18% -164.23M -201.43% -927.18M -444.75% -3.37B 11.55% 4.25B
Minority interest income
Net income attributable to the parent company
-104.18% -164.23M -201.43% -927.18M -444.75% -3.37B 11.55% 4.25B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-104.18% -164.23M -201.43% -927.18M -444.75% -3.37B 11.55% 4.25B
Basic earnings per share
-104.19% -5.52 -201.34% -31.12 -443.52% -112.57 11.32% 142.33
Diluted earnings per share
-104.25% -5.52 -202.64% -31.12 -447.65% -112.57 11.38% 140.56
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
CEO: Mr. Norman Schwartz
Market: NYSE
Listing Date: 10/24/2008
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist